Summary Studies in animal models of mouse mammary carcinoma have shown that ovine submaxillary mucin, which carries multiple sialyl-Tn (STn) epitopes, is effective in stimulating an immune response and inhibiting tumour growth. In similar studies using carbohydrate antigens, pretreatment with low-dose cyclophosphamide has been shown to be important in modulating the immune response to antigen possibly by inhibiting suppresser T-cell activity. In a clinical trial assessing the efficacy and toxicity of synthetic STn, patients with metastatic breast cancer were randomised to receive 100 ug STn linked to keyhole limpet haemocyanin (KLH) with DETOX-B adjuvant given by subcutaneous injection at weeks 0, 2, 5 and 9 with or without low-dose cyclophosphamide (CTX, 300 mg m2) pretreatment, 3 days before the start of immunotherapy. Patients with responding or stable disease after the first four injections were eligible to receive STn-KLH at 4 week intervals. The main toxicity noted was the development of subcutaneous granulomata at injection sites. Of 23 patients randomised, 18 received four injections, 5 patients having developed progressive disease during the initial 12 week period. Two minor responses were noted in the 18 patients who received four active specific immunotherapy (ASI) injections and a further five patients had stable disease. Six patients continued ASI at 4 week intervals and a partial response was noted in a patient who had previously had stable disease. All patients developed IgG and IgM responses to sialyl-Tn and levels of IgM antibodies were significantly higher in those patients who were pretreated with CTX. Measurable tumour responses have been recorded following ASI with STn-KLH plus DETOX and the immunomodulatory properties of low-dose CTX have been confirmed.
Sialyl-Tn (STn) is defined by the structure NANAc(2-6)GaINAc and is a carcinoma-associated core region carbohydrate antigen of epithelial mucin. Expression of sialyl-Tn is associated with a poor prognosis in colon (Itzkowitz et al., 1990) , gastric (Miles et al., 1995) , ovarian (Kobayashi et al., 1992) and breast cancer (Miles et al., 1994) , and may therefore be a relevant target for the potential immunotherapy of such tumours (Longenecker et al., 1993) .
Studies in animal models have demonstrated slowing of tumour growth and prolongation of survival following immunisation with carbohydrate antigens (Fung et al., 1990; Singhal et al., 1991) . In a phase I study in patients with metastatic breast cancer, immunisation with a synthetic STn linked to keyhole limpet haemocyanin (KLH) and given with an immunological adjuvant (DETOX-B) led to development of hapten-specific IgM and IgG antibodies in all patients (MacLean et al., 1993) . In this study, 2 of 13 evaluable patients had a partial response to immunotherapy.
A potential method of increasing the immunogenicity of tumour vaccines is the use of cyclophosphamide (CTX) before immunisation. Low-dose CTX (200-300 mg m-2) given 2-4 days before antigen administration enhances humoral and cellular responses to vaccine immunisation in tumour-bearing animals (Glaser, 1979; Havas and Schiffmann, 1981 ) and in man (Berd et al., 1984; Fagerberg et al., 1995) . It has been suggested that this effect is a result of inactivation of suppressor T-lymphocytes which downregulate responses to novel antigens (Bonavida et al., 1979; Berd and Mastrangelo, 1988) . In malignant melanoma, CTX pretreatment has been reported to augment cellular immunity induced by a melanoma vaccine in patients with metastatic disease (Berd and Mastrangelo, 1988) but not in patients with a low tumour burden (Oratz et al., 1991) .
The randomised phase II study reported here was designed to assess whether pretreatment with low-dose CTX enhanced the immune response to sialyl-Tn-KLH with DETOX-B in patients with metastatic breast cancer. al., 1977) . Tumour responses were classified as follows: (1) complete response, disappearance of all evidence of disease; (2) partial response, > 50% reduction in the sum of the product of the two largest perpendicular diameters of all measurable lesions with no new lesions appearing; (3) minor response, >25% but <50% reduction in tumour lesions; (4) stable disease, changes insufficient to enable classification into categories 3 or 4, i.e. a decrease in the area of all tumours less than 25% or an increase in tumour lesions less than 25%; (5) progressive disease, appearance of new lesions or a > 25% increase in the product of the two largest perpendicular diameters of any individual lesion.
Methods
Time to disease progression was measured from the date the patients started treatment to the date of detection of progression of previously described lesions at baseline or detection of new lesions. Twenty-three patients with metastatic breast cancer were entered into this randomised phase II study of STn-KLH in DETOX-B adjuvant with or without cyclophosphamide pretreatment. Patient characteristics are illustrated in Table  I . Median age of the patient group was 56 years (range 36-73 years) and initial disease-free interval was 42 months (range 9-89 months). Seventeen patients had received prior endocrine therapy and 12 patients prior chemotherapy for metastatic disease. Twenty patients had <two sites of disease and the majority of sites were nodal and cutaneous deposits. There were no significant differences in the above parameters between the two patient groups (Mann -Whitney U and Fisher's exact tests).
Eighteen patients completed at least four vaccinations according to the protocol. Five patients were withdrawn from the study before the first formal assessment because of progressive disease which required alternative systemic therapy.
Of Following injection of STn-KLH plus DETOX-B, all patients developed erythema at injection sites which peaked at 24-48 h after injection and resolved completely after a few days. Seventeen patients developed granulomata at the injection sites which increased in size with subsequent injections of ASI (maximum median diameter 10 mm, range 5-60 mm, no significant differences between the two groups, Mann-Whitney U-test). In nine patients ulceration of the granulomata occurred and in four patients DETOX-B was (Figure 2 ), the differences were not statistically significant. The levels of IgM antibodies to STn-HSA and OSM were significantly higher in the group which had received cyclophosphamide pretreatment (Figure 2 ).
Discussion
Specific humoral immune responses to carbohydrate antigens have been demonstrated previously in animal models and patients with breast, ovarian and colorectal cancer. Studies using synthetic carbohydrate antigens in patients with breast and ovarian cancer have previously demonstrated the specificity of the anti-hapten humoral immune response (MacLean et al., 1992 (MacLean et al., , 1993 . In the phase I study of sialylTn in patients with metastatic breast cancer, two partial responses were noted in 13 patients and two patients had mixed responses (reduction in tumour burden at some sites and progression in other sites; MacLean et al., 1993) .
Studies in animal models have suggested that the immune response may be augmented by pretreatment with low-dose cyclophosphamide, possibly by inhibition of a subset of putative suppressor T-lymphocytes (Mastrangelo and Berd, 1988) . Studies comparing the effects of i.v. CTX vs no pretreatment on cell-mediated immunity in patients receiving vaccine therapy for melanoma have yielded contradictory results (Mastrangelo and Berd, 1988; Oratz et al., 1991) possibly as a result of differences in tumour burden at the time of treatment.
We report here the results of a randomised phase II study assessing the effect of low-dose cyclophosphamide pretreatment on the immune response to the synthetic carbohydrate antigen, sialyl-Tn, conjugated to KLH and given with an immunological adjuvant. The systemic toxicity of the treatment schedule was low with only transient nausea in those receiving CTX and mild 'flu-like symptoms associated with ASI injections. The main toxicity of ASI was the development of granulomas at injection sites and subsequent ulceration. Omission of DETOX-B from the ASI formulation alleviated this problem during subsequent treatment courses. Measurable reductions in tumour burden were noted in two patients following the four initial ASI injections, although changes in dimensions of measurable lesions were not sufficient to be categorised as a partial response according to standard UICC criteria. Both these minor responses occurred in patients who did not receive CTX pretreatment and who had minimal bulk metastatic disease. A partial response was noted in a breast mass following four further ASI injections and, although this occurred in a patient who received CTX pretreatment, the response was documented 29 weeks following the CTX pretreatment and could not therefore be attributed to a direct anti-tumour action of this drug.
Following STn-KLH with DETOX, all patients developed IgM and IgG responses to sialyl-Tn, although antibody responses were lower when measured using OSM compared with synthetic hapten. This has been noted previously (Longenecker et al., 1993) the possibility that this approach could influence progressionfree interval, for example following chemotherapy for metastatic disease, should be addressed. The study has also demonstrated that even in this heavily pre-treated group of patients. low-dose CTX can augment the humoral immune response to antigen and its inclusion in future studies of specific immunotherapy in cancer should be considered.
